
Aurora Cannabis ACB
$ 4.28
-1.41%
Annual report 2025
added 01-03-2026
Aurora Cannabis EV/EBITDA Ratio 2011-2026 | ACB
Annual EV/EBITDA Ratio Aurora Cannabis
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.99 | -3.12 | -29.2 | -36.9 | -56.7 | -13.7 | -2.7 | -23.1 | 0.3 | -0.573 | -86.4 |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.3 | -86.4 | -23.2 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals
ZYNE
|
-0.574 | - | - | $ 55.5 M | ||
|
Alimera Sciences
ALIM
|
4.15 | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.2 | 0.42 % | $ 129 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-2.97 | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
-14.5 | $ 2.69 | -0.56 % | $ 1.42 B | ||
|
Agile Therapeutics
AGRX
|
-18.5 | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
22.8 | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
1.47 | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-1.77 | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-0.0195 | - | -0.1 % | $ 2.03 B | ||
|
Evoke Pharma
EVOK
|
-27.4 | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-1.44 | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
7.77 | $ 12.84 | 2.8 % | $ 657 M | ||
|
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | $ 21.5 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
-9.74 | $ 6.03 | -10.27 % | $ 374 M | ||
|
Harrow Health
HROW
|
72.8 | $ 54.06 | 8.3 % | $ 1.76 B | ||
|
Jupiter Wellness
JUPW
|
-50.5 | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
51.8 | $ 1.23 | 1.65 % | $ 21.5 M | ||
|
OrganiGram Holdings
OGI
|
-2.79 | $ 1.7 | -1.74 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
18.6 | $ 7.51 | 4.16 % | $ 2.74 B | ||
|
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
0.202 | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-19.4 | $ 3.95 | -0.77 % | $ 55.5 M | ||
|
Organogenesis Holdings
ORGO
|
15.8 | $ 4.36 | -5.93 % | $ 574 M | ||
|
Sundial Growers
SNDL
|
-1.27 | $ 1.72 | -1.41 % | $ 3.37 M | ||
|
Pacira BioSciences
PCRX
|
29.6 | $ 25.21 | 3.07 % | $ 1.17 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 3.73 | 2.46 % | $ 4.63 M | ||
|
Rockwell Medical
RMTI
|
-13.7 | $ 0.98 | 13.92 % | $ 22.9 M | ||
|
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
11.2 | $ 14.36 | 3.42 % | $ 1.97 B | ||
|
ProPhase Labs
PRPH
|
9.86 | - | - | $ 5.07 M | ||
|
Veru
VERU
|
31.2 | $ 2.28 | 0.58 % | $ 308 M | ||
|
Radius Health
RDUS
|
-13.2 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
13.4 | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
-2.7 | $ 1.11 | -4.31 % | $ 4.79 M | ||
|
Relmada Therapeutics
RLMD
|
-2.91 | $ 4.11 | -6.06 % | $ 124 M | ||
|
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
7.11 | $ 9.62 | 5.25 % | $ 683 M | ||
|
PLx Pharma
PLXP
|
-1.81 | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-0.17 | $ 5.33 | -2.14 % | $ 218 M | ||
|
SCYNEXIS
SCYX
|
-1.32 | $ 0.64 | -0.03 % | $ 30.6 M | ||
|
Tricida
TCDA
|
-3.32 | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
-46 | $ 9.43 | -3.03 % | $ 5.83 B | ||
|
TherapeuticsMD
TXMD
|
-45.5 | $ 1.79 | 8.78 % | $ 18.7 M | ||
|
Zomedica Corp.
ZOM
|
8.79 | - | -0.21 % | $ 98 M |